GlaxoSmithKline plc (GSK)

📖 Wiki Page

company853 wordssynced 2026-04-02

Overview

flowchart TD companies_glaxosmithkline["GlaxoSmithKline plc GSK"] style companies_glaxosmithkline fill:#4fc3f7,stroke:#333,color:#000 companies_glaxosmith_0["Company Information"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_0 style companies_glaxosmith_0 fill:#81c784,stroke:#333,color:#000 companies_glaxosmith_1["Business Structure"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_1 style companies_glaxosmith_1 fill:#ef5350,stroke:#333,color:#000 companies_glaxosmith_2["Corporate Overview"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_2 style companies_glaxosmith_2 fill:#ffd54f,stroke:#333,color:#000 companies_glaxosmith_3["Research and Development"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_3 style companies_glaxosmith_3 fill:#ce93d8,stroke:#333,color:#000 companies_glaxosmith_4["Neuroscience Pipeline"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_4 style companies_glaxosmith_4 fill:#4fc3f7,stroke:#333,color:#000 companies_glaxosmith_5["Alzheimers Disease Programs"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_5 style companies_glaxosmith_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

GlaxoSmithKline (GSK) is a British multinational pharmaceutical company headquartered in London, with operations in over 100 countries. The company has maintained a strategic interest in neuroscience, with particular focus on neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.[@glaxosmithkline][@gsk2024]

Business Structure

Corporate Overview

GSK operates as one of the world's largest pharmaceutical companies with three main business divisions:

Vaccines: Leading vaccine developer and manufacturer

Specialty Medicines: Oncology, immunology, and rare diseases

General Medicines: Broad portfolio of established medicines

Neuroscience research falls primarily within the Specialty Medicines division.

Research and Development

GSK maintains significant R&D operations:

Global R&D centers in UK, US, and Belgium
Focus on human genetics and immunology
Emphasis on targeted therapies and biomarkers

Neuroscience Pipeline

Alzheimer's Disease Programs

| Program | Target | Mechanism | Stage |
|---------|--------|-----------|-------|
| Tau programs | Tau protein | Various approaches | Discovery |
| OT-805 | Tau | Antibody | Preclinical |
| AL101 collaboration | Progranulin | Antibody | Phase 2 (with Alector) |
| Neuroinflammation | TREM2, IL-34/CSF-1R | Immunomodulation | Research |
| [Gamma-secretase](/entities/gamma-secretase) | [APP](/entities/app-protein) processing | Modulator | Previous trials |

Parkinson's Disease Programs

| Program | Target | Mechanism | Stage |
|---------|--------|-----------|-------|
| [LRRK2](/entities/lrrk2) programs | LRRK2 kinase | Kinase inhibitors | Discovery |
| [GBA](/entities/gba) programs | Glucocerebrosidase | Chaperones | Preclinical (with Gain) |
| Alpha-synuclein | α-Syn | Various approaches | Research |
| Mitochondrial targets | Mitochondrial dysfunction | Neuroprotection | Research |

Other CNS Programs

GSK maintains research programs in:

Multiple CNS disorders
Neuropsychiatric conditions
Pain and sensory disorders
Rare neurological diseases

Technology Platform

GSK's neuroscience research leverages:

Genomics and genetics: Target discovery through human genetics
Immunology expertise: Neuroinflammation modulation approaches
Gene therapy: Exploring gene therapy for neurological disorders[@gsk]
Small molecule platform: Kinase inhibitors for CNS targets

Key Research Capabilities

Human Genetics: Leveraging UK Biobank and genetic databases

Immunology: Applying immunological expertise to neuroinflammation

RNAi/siRNA: RNA interference technologies

AAV vectors: Adeno-associated virus for gene delivery

Drug Discovery Approach

GSK employs multiple modalities:

Small molecule inhibitors
Monoclonal antibodies
Gene therapy vectors
RNA-based therapeutics

Research Focus

Alzheimer's Disease Research

GSK's Alzheimer's research includes:

Tau-targeting therapeutics: Including OT-805 in partnership
Amyloid research: Through partnerships with biotech companies
Neuroinflammation modulation: TREM2, IL-34/CSF-1R pathways
Synaptic plasticity: Memory restoration approaches
Genetic risk factors: [APOE](/proteins/apoe), TREM2, and other GWAS hits

Parkinson's Disease Research

Parkinson's programs focus on:

LRRK2 inhibitor research: GSK'257 and related compounds
Alpha-synuclein targeting: Multiple modalities
Neuroprotective strategies: Disease modification
Mitochondrial dysfunction pathways: Targeting energy metabolism
GBA-related PD: Collaborations with Gain Therapeutics

Strategic Partnerships

Biotechnology Collaborations

Alector: AL101 (progranulin antibody) — 50-50 US profit share, tiered royalties ex-US
Gain Therapeutics: GCase modulators for PD
Tau-targeting biotech: Various collaborations on tau programs
Gene therapy companies: AAV delivery partnerships

Academic Partnerships

Oxford University: Neuroscience research collaboration
Cambridge University: Neurodegeneration research
UK Dementia Research Institute: Dementia research initiatives

Consortium Involvement

Parkinson's Progression Markers Initiative (PPMI): Disease progression research
CRANBERRY Project: EU-funded neurodegeneration biomarker research[@cranberry]
Michael J. Fox Foundation: LRRK2 genetics collaboration

Clinical Trial History

Alzheimer's Disease Trials

GSK has conducted multiple AD trials:

Gamma-secretase modulator trials (completed)
Multiple Phase 1/2 studies
Current Phase 2 trials with Alector

Parkinson's Disease Trials

LRRK2 inhibitor studies
Neuroprotective agent trials
Combination therapy trials

Key Leadership

Emma Walmsley (CEO) — Leading company's strategic direction
Dr. Tony Wood (Chief Scientific Officer)
Dr. John Kemp (Former Head of Neuroscience Research)

Financial Overview

| Metric | Value |
|--------|-------|
| Market Cap | ~$85 billion |
| Annual Revenue | ~£30 billion |
| R&D Investment | ~£5 billion/year |
| Neuroscience (est.) | 5-8% of R&D |

Relevance to Neurodegeneration

GSK's neuroscience programs address key mechanisms in neurodegenerative diseases:

[Tau](/proteins/tau) — Neurofibrillary tangles and disease progression
[LRRK2](/genes/lrrk2) — Parkinson's disease kinase
[Alpha-synuclein](/proteins/alpha-synuclein) — Lewy body pathology
[TREM2](/proteins/trem2) — Microglial activation and neuroinflammation
[Neuroinflammation](/mechanisms/neuroinflammation) — Glial activation
[GBA1](/genes/gba1) — Glucocerebrosidase and PD risk
[Progranulin](/proteins/progranulin-protein) — Frontotemporal dementia

Cross-References

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Tau Protein](/proteins/tau)
[LRRK2](/genes/lrrk2)
[TREM2](/proteins/trem2)
[Alpha-synuclein](/proteins/alpha-synuclein)
[Progranulin](/proteins/progranulin-protein)
[Alector](/companies/alector)
[Gain Therapeutics](/companies/gain-therapeutics)

External Links

[GSK Official Website](https://www.gsk.com/)
[GSK Research](https://www.gsk.com/en-us/research/)
[GSK Annual Report 2024](https://www.gsk.com/en-us/investors/annual-report/)
[GSK Pipeline](https://www.gsk.com/en-us/research/pipeline/)
[ClinicalTrials.gov](https://clinicaltrials.gov)

References

Unknown, GlaxoSmithKline - Wikipedia (n.d.)

Unknown, GSK Annual Report 2024 (2024)

Unknown, GSK Neuroscience Research (n.d.)

Unknown, CRANBERRY Project - EU Neurodegeneration Research (n.d.)

[Kemp J, et al., LRRK2 Kinase Inhibitors: From Discovery to Clinical Development. J Parkinsons Dis. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33877204/)

📖 View canonical wiki page →